Fig 1.

Immunohistochemical and radiographic findings in a patient with metastatic BCC treated with pembrolizumab overlapping with radiotherapy and surgery. A, Significant PD-L1 expression in the recurrent shoulder BCC (arrow) and peritumoral infiltrate (double arrow) using mouse anti–PD-L1 monoclonal antibody, clone 2B11D11, Proteintech). (Original magnification: ×200.) B, CT image of pulmonary metastases with arrow indicating example lesion before pembrolizumab (red arrow). C, After 6 weeks of pembrolizumab, this lesion completely resolved (red arrow).